In an assessment of trigger point dry needling as a treatment for orchialgia, an analysis of self-reported improvement data from 2009 to 2016, as well as NIH Chronic Prostatitis Symptom Index (NIH-CPSI) data, showed that 85% of patients who underwent pelvic floor trigger point dry needling as a component of physical therapy (PT) indicated their orchialgia improved.
To evaluate the benefit of physical therapy for orchialgia in previously treated patients, researchers conducted a retrospective review of patient data for men who underwent pelvic floor PT after going through other treatments, including non-steroidal anti-inflammatory drugs, antibiotics, surgery, nerve block, narcotics, and previous pelvic floor PT. Results showed an improvement in NIH-CPSI pain and quality of life categories for all patients who received previous orchialgia treatment.
A randomised controlled study of 108 patients with prostatitis, but without erectile dysfunction, evaluated the efficacy and safety of a daily low dose tadalafil added to levofloxacin for the treatment of chronic prostatitis/chronic pelvic pain syndrome.
The study concluded low dose tadalafil added to levofloxacin as treatment is well tolerated and significantly improved chronic prostatitis/chronic pelvic pain syndrome related symptoms.
The AUA, an advocate for the specialty of urology, has more than 21,000 members throughout the world. The association encourages scientific research, education and formulation of health care policy in the field of urologic medicine.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study